Legal & General Group PLC Beyond Spring Inc. Transaction History

Legal & General Group PLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$0.97 - $1.81 $5,128 - $9,569	-5,287 Closed	0 $0
Q2 2022 Aug 22, 2022	SELL	$1.13 - $2.66 $628 - $1,478	-556 Reduced 9.52%	5,287 $8,000
Q3 2021 Nov 15, 2021	BUY	$9.26 - $31.31 $31,854 - $107,706	3,440 Added 143.15%	5,843 $92,000
Q2 2021 Aug 12, 2021	BUY	$9.37 - $12.12 $4,169 - $5,393	445 Added 22.73%	2,403 $25,000
Q1 2021 May 17, 2021	BUY	$10.61 - $15.77 $3,098 - $4,604	292 Added 17.53%	1,958 $22,000
Q3 2020 Nov 13, 2020	SELL	$9.99 - $16.13 $4,945 - $7,984	-495 Reduced 22.91%	1,666 $22,000
Q2 2020 Aug 14, 2020	BUY	$11.21 - $18.15 $11 - $18	1 Added 0.05%	2,161 $32,000
Q1 2020 May 14, 2020	SELL	$9.68 - $18.47 $4,917 - $9,382	-508 Reduced 19.04%	2,160 $27,000
Q4 2019 Feb 13, 2020	BUY	$11.83 - $18.68 $5,560 - $8,779	470 Added 21.38%	2,668 $41,000
Q3 2019 Nov 13, 2019	BUY	$15.33 - $23.85 $6,269 - $9,754	409 Added 22.86%	2,198 $40,000
Q2 2019 Aug 14, 2019	BUY	$13.36 - $23.7 $23,901 - $42,399	1,789 New	1,789 $40,000

5.77M

53.2K

2.5K

Ticker BYSI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,928,900
Market Cap $85.6M
Description
BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immune-modulating microtubule-binding agent that has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia; and...

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

Stay updated on Legal & General Group PLC with notifications on news.